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INTRODUCTION 
Ebola virus (EBOV) is the deadly etiological agent of 
Ebola viral disease (EVD), earlier known as Ebola 
hemorrhagic fever. It belongs to the Filovirus family and 
order Mononegavirales, which contains negative-sense 
single-stranded RNA with a protective envelope 
(Geisbert & Jahrling, 1995). The first outbreak was 
recorded in 1976, following which EVD outbreaks have 
proved to be persistently pandemic while the mortality 
rate is 90% (Feldmann & Geisbert, 2011). According to 
WHO, five strains of EBOV have been identified, causing 
a total of 25 outbreaks and differentiated based on 
virulence properties and geographical patterns observed 
(Picazo & Giordanetto, 2015). Zaire Ebola virus (ZEBOV), 
BundibugyoEbola virus (BDBV), Reston Ebola virus 
(RESTV), Sudan Ebola virus (SUDV), and Taï Forest 
Ebola virus (TAFV) are the five strains named after the 
places affected by the outbreaks. The latest outbreak in 
2014 was caused by the most lethal Zaire strain in West 
Africa, resulting in 11,000 deaths (Baize et al.., 2014). 
Though the reservoirs are yet to be confirmed, fruit bats, 
gorilla, antelopes and chimpanzees are considered to be 
potential hosts for serious transmission (Ascenzi et al., 
2008). Followed by this, in humans, it is spread through 
blood and contact with fluid body secretions. The 
infection projects itself in two phases with symptoms 
ranging from fever, fatigue, rashes, vomiting in the early 
phase, whereas in the late phase hemorrhagic shock 
occurs eventually resulting in death (Chiappelli et al., 
2015). Several diagnostic and laboratory tests are used to 
examine this deadly virus. Some of the investigations are 
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 Abstract 
Ebola viral disease (EVD) is a deadly infectious hemorrhagic viral 
fever caused by the Ebola virus with a high mortality rate. Until date, 
there is no effective drug or vaccination available to combat this 
condition. This study focuses on designing an effective antiviral drug 
for Ebola viral disease targeting viral protein 30 (VP30) of Ebola virus, 
highly required for transcription initiation. The lead molecules were 
screened for Lipinski rule of five, ADMET study following which 
molecular docking and bioactivity prediction was carried out. The 
compounds with the least binding energy were analyzed using 
interaction software. The results revealed that 6-Hydroxyluteolin and 
(-)-Arctigenin represent active lead compounds that inhibit the activity 
of VP30 protein and exhibits efficient pharmacokinetics. Both these 
compounds are plant-derived flavonoids and possess no known 
adverse effects on human health. In addition, they bind strongly to the 
predicted binding site centered on Lys180, suggesting that these two 
lead molecules can be imperative in designing a potential drug for 
EVD. 
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CBC profile, ELISA, RT-PCR and cell culture techniques 
(Broadhurst et al., 2016). 
The filamentous EBOV is composed of approximately 
19kb genome (Yu et al., 2017; Zhao, 2016) with genes 
coding for 4 structural proteins such as VP30, VP35, 
nucleoprotein (NP), polymerase protein and three 
membrane-associated proteins such as VP40, 
glycoprotein and VP24 (Mühlberger, 2007; Easton et al., 
2018). The two molecular forms of viral glycoprotein 
(GP1 & GP2) in combination with host proteins like 
Niemann-Pick C1 (NPC1) mediate viral entry (Lee & 
Saphire, 2009). Once the viral attachment is complete 
through the GP1 – host cellular receptor interaction, the 
virions enter the cell through endocytosis. The three-
domain matrix protein VP40 facilitates virion maturation 
and viral assembly (Hoenen et al., 2005). VP40, which is 
present profusely, also maintains viral integrity (Passi et 
al., 2015). VP35 is bi-functional by both being a part of 
viral replication and also inhibiting IFNs production in 
the host cell (Basler, 2015). 
The nucleoprotein, along with RNA, forms the helical 
complex whereas VP24 inhibits host STAT1 signaling 
pathway and mediates nucleocapsid formation. The 
phosphoprotein VP30, 30 KDa in size, is a major 
component for viral RNA synthesis and initiates 
transcription (Cantoni & Rossman, 2018). The interaction 
of VP30 with nucleocapsid (NP) brought by the 
phosphorylation of the N-terminal region, directly affects 
the transcription process (Biedenkopf et al., 2013). Thus, 
the VP30 bound NP complex is required for transcription 
initiation (Weik et al., 2002). The ribonucleoprotein is 
released from the virion and serves as a template for 
transcription. Mutation studies reveal that the 
Phosphorylation sites of VP30 at serine residues is the 
core requirement for transcription (Martínez et al., 2008).  
At present, there is no licenced anti-viral treatment 
available for EVD (Schuler et al., 2017). Factors such as 
high resistance, the requirement of advanced biosafety 
levels in clinical trials and the need for further exploration 
of pathophysiology and complex molecular mechanism 
makes it highly challenging to combat EBOV (Dhama et 
al., 2018). Several in silico drug design approaches prove 
potentially useful for developing anti-viral drugs against 
EBOV disease as computational biology provides 
various tools to obtain inherent knowledge of protein 
structure and interactions to identify potential lead 
molecules (Schuler et al., 2017). Also, they aim to simulate 
models of the real world that requires validation through 
wet-lab experiments. 
Most of the Ebola drug design research focuses on 
targeting VP35 and VP40 because of their importance in 
viral replication and assembly (Nasution et al., 2018; Roca 
et al., 2015) but the recent findings describe that 
intermolecular interactions between VP30 and NP 
regulate viral mRNA synthesis. NP binds to VP30 at a 
strongly conserved region in a narrow groove (Xu et al., 
2017). This indicates that VP30 is a promising drug target 
to block viral replication at the initial stage. Hence, this 
computational approach identified and analyzes the 
properties of drug-likeness to filter compounds and were 
subjected to molecular docking identifying potential 
inhibitors based on binding energy and interaction 
properties. 
 
MATERIALS AND METHODS 
Identification of lead molecules 
One hundred and twenty lead molecules with known 
antiviral properties were selected from literature search 
(De Clercq, 2015; Huggins et al., 1999; Kouznetsova et al., 
2014; Schuler et al., 2017; Shen et al., 2015; Vlietinck et al., 
1998). These 120 compounds were from both synthetic 
and non-synthetic (plant) sources. The SMILES file 
format of the compounds were retrieved from PubChem 
database (Kim et al., 2016). SMILES are line notations 
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distinct for different structures that are required to obtain 
two-dimensional and three-dimensional models of the 
molecules. Later the SMILES format was converted into 
PDB format using online CORINA server that generates 
3D structures (Sadowski et al., 1994). 
Protein structure preparation 
The protein crystal structure of Ebola VP30 protein (PDB 
code: 5DVW) with the resolution of 1.75Å was retrieved 
from RCSB Protein Data Bank (PDB), a repository 
providing crystal structures of biotic macromolecules 
(Berman et al., 2000). The data in PDB is deposited from 
various researches based on the results of X-ray 
crystallography and NMR spectroscopy and is validated 
using defined standards of stereochemistry (Gore et al., 
2017). The water molecules and heteroatoms were 
removed, and the protein molecule was subjected to 
energy minimization using Swiss PDB Viewer, a tool for 
comparative protein analysis (Guex & Peitsch, 1997). 
Analyzing properties of drug-likeness 
All the 120 lead compounds were analyzed for Lipinski 
rule satisfaction and subjected to ADMET analysis using 
pkCSM online server (Pires et al., 2015). Lipinski rule of 
five is the primary criteria to evaluate small lead 
molecules. This aids in discerning capable drug-like 
molecules using filters and thus enabling to predict 
clinical success with higher probability. The five 
parameters of this rule (Lipinski, 2004), demands the 
molecular weight to be higher than 500, more than five 
hydrogen donors and greater than 10 Hydrogen 
acceptors. Also, the Log P- value should be greater than 
5.0 and with ten or more than ten rotatable bonds. The 
first three parameters correlate with 90% clinical success. 
Rotational bonds higher than ten indicate low 
bioavailability and the ideal value of log P or log D 
indicating lipophilicity is between 0-3. Compounds that 
met these criteria were subjected to ADMET analysis.   
ADMET analysis allows to quickly scan through 140 
properties to identify lead compounds that are potential 
with high binding affinity and non-toxic to the human 
body while absorption and distribution rate are other key 
factors (Venkatesan et al., 2018). Performing ADMET tests 
in vivo are highly time-consuming and are not cost-
effective. Computational tools serve to provide quick 
screening of toxicity and pharmacokinetic properties. 
One such tool is pkCSM that represent chemical entities 
mathematically based on graphical modeling. Some 
parameters are drug-specific, and in our study 
parameters such as water solubility, intestinal 
permeability, not less than 30%, CaCO-2 permeability 
that predicts absorption of orally administered drugs, 
AMES toxicity to test mutagenicity, hepatotoxicity and 
inhibition of hERG potassium channels which indicates 
the drug can lead to QT syndrome were considered. 
Finally, the filtered compounds were subjected to 
molecular docking study. 
Binding site analysis of VP30 
The functional residues of VP30 were analyzed to know 
the active binding site. Based on mutagenesis analysis 
ARG179, LYS180, and LYS183 in the secondary 
nucleoprotein VP30 have been identified as the base 
residues, which are involved in consorting itself with the 
nucleocapsid activation of transcription (de La Vega et al., 
2015). Mutations in these residues lead to loss of 
transcription function. The binding site centered on Lys 
180 can thus be considered as an expedient target for 
small inhibitory molecules (Salata et al., 2019). CASTp 
server (Binkowski et al., 2003) is an online resource for 
studying surface topography and functional region of 
proteins used to analysis binding site residues. It depicts 
concave cavities on protein surfaces and allows the user 
to explore the interior of the protein providing 
information about the functional notations. 
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Molecular docking 
Molecular docking is an in silico tool that has an 
increasing significance in drug design (de Ruyck et al., 
2016). It allows characterization of protein-ligand 
interaction at the atomic level and combines the 
properties of quantum and molecular mechanics 
(Aminpour et al., 2019). The requisites of docking include 
the tertiary structure of the protein, pdbqt format of 
ligand, binding mode and involves four classes of 
scoring. While docking can be rigid or flexible, we 
performed rigid docking where the bond length and 
angles are kept constant. Compounds filtered from 
ADMET analysis were subjected to docking using 
AutoDock 4.2 (Forli et al., 2016). Protein preparation is the 
vital step of docking that requires the removal of water 
molecules, whereas hydrogen atoms and Kollman 
charges were added (Xie et al., 2015). The size of the grid 
box was set to 84 × 90 × 92 to enable docking only within 
the binding site. A threshold of -6.5 kcal/mol was set to 
select potential inhibitors. The Lamarckian genetic 
algorithm was used to allow flexible docking between 
ligands and the receptor. Out of 10 confirmations 
obtained, the first two compounds with the least binding 
energy were taken as the best-docked conformations 
(Garcia-Godoy et al., 2015). The docking results were 
analyzed by comparing with the control drug BCX4430, 
an antiviral adenosine analog from BioCryst 
Pharmaceuticals. It blocks the function of viral 
polymerase and acts against a broad range of Filovirus by 
instigating RNA chain termination (Warren et al., 2014). 
Intramuscular injection of this drug confers protection in 
rodents exposed to EBOV, thus, making it a controlled 
drug for docking studies of EBOV (Raj & Varadwaj, 
2016). The control drug was docked with VP30, and its 
interactions were studied in similar conditions. The 
docking results were visualized using PyMOL software 
that delivers high-quality 3D images of the ligand-bound 
to its protein (Seeliger & de Groot, 2010). The interacting 
residues for the control and test compounds were 
analyzed using LigPlot+, a graphical system that reads 
3D coordinates and fosters details of protein-ligand 
interaction as several two-dimensional figures 
(Laskowski & Swindells, 2011). 
Bioactivity score prediction 
In silico screening of structural properties related to the 
pharmacological activity of the selected molecules can 
aid in understanding their similarity to the known drugs. 
Molinspiration, a web-based tool was utilized to calculate 
the bioactivity score of the best-docked complexes and 
the control drug. Indispensable properties involved for a 
lead molecule to bind to its receptors of drug target like 
GPCRs, nuclear receptors, ion channel modulation, 
inhibition of kinases, proteases and enzymes were 
calculated (Khan et al., 2017). The input is imported as 
SMILES structure, and the predicted bioactivity of the 
screened compounds is given as a numerical score 
between -5 and +5. 
 
RESULTS AND DISCUSSION 
ADMET results and active site residues 
This computational study was initiated with the 
screening of retrieved 120 antiviral compounds for 
ADMET properties. The results from pkCSM tool for 
Lipinski rule and ADMET analysis filtered thirty-six lead 
molecules fulfilling all five criteria of Lipinski rule with 
acceptable solubility, absorption and possess no known 
toxic or mutagenic effects were shown in 
Supplementary Table I. The protein structure of VP30 
from PDB is a homodimer with four chains. The binding 
residues of protein structure from CASTp include 
ARG168, THR172, ARG179, LYS180, PHE181, SER182, 
LYS183, HIS215, SER216, ASP217, LYS218, GLY219, 
GLY220, GLU223, GLU252, SER254, VAL256 and 
VAL257. These were in par with the earlier studies with 
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binding residues centred on LYS180, vital for 
transcription initiation and nucleocapsid interaction 
suggested by mutagenesis analysis (Hartlieb et al., 2007). 
Molecular docking 
These thirty-six compounds were subjected to molecular 
docking to anticipate the protein-ligand binding 
affinities, modes of interaction and inhibition activity. 
Compounds with the least binding energy are known to 
be better hits (Venkatesan & Febin, 2017) and based on 
the set threshold (binding energy < -6.5 kcal/mol), 10 
compounds were selected. Further results from LigPlot+ 
revealed that two out of ten compounds with 
PubChemId 5281642 and 64981 are the most effective of 
all. Both are phytochemicals with previously reported 
antiviral activity (Vlietinck et al., 1998) and binds at the 
predicted active binding site forming strong hydrogen 
bonds. Visualising docking results revealed that ten 
amino acid residues are in contact with Compound 1 and 
13 amino acids with compound 2. 
Binding mode analysis of control compound BCX4430 
Docking VP30 with BCX4430 indicates binding energy of 
-4.16 kcal/mol with 11 amino acids in contact with three 
hydrogen bonds GLU191, ALA255 and ASP217. Among 
these residues, only ASP217 belong to the predicted 
active site. Two more hydrogens bonds were visualized 
within BCX4430 atoms stabilizing the complex. Residues 
involved in hydrophobic interactions were ARG179, 
LYS183, VAL256, SER253, LEU218, GLY220, GLY219, 
LEU188. The intermolecular energy was -5.95 kcal/mol, 
which involves both desolvation and electrostatic energy. 
This indicates the energy of non-bounded atoms. The 
total internal energy was -1.93 kcal/mol explaining the 
total of all energy changes and entropy.  
Binding mode analysis of compound 1 
Compound 1-6-Hydroxyluteolin (PubChem ID: 
5281642) also called as 5,6,7,3 ,ˈ4ˈ-pentahydroxyflavone is 
a flavonoid isolated from Valerianella eriocapa (Italian corn 
salad) and also found in other herbs and spices (Yannai, 
2003). Unlike other antiviral compounds, flavones have a 
wide range of activity. Though the action of flavones in 
ebola is not fully explored, it is possibly by binding to a 
glycoprotein of RNA virus (Vlietinck et al., 1998) blocking 
VP30 interaction with GP necessary for EBOV 
transcription. The binding energy of this compound was 
-7.71 kcal/mol forming one hydrogen bond within itself 
and five hydrogen bonds with LYS180, GLU252, LYS218, 
ASP217 and ARG179 residues that were a part of 
predicted binding site of VP30. The hydrophobic 
interactions of ligand were with ARG179, LYS180, 
PHE181, HIS215 and SER216 of VP30. The 
intermolecular energy was -7.99 kcal/mol with the total 
internal energy being -1.37 kcal/mol. 
Binding mode analysis of compound 2 
The second compound (-)-Arctigenin (PubChem ID: 
64981) is a lignanolide of the dibenzyl butyrolactone type 
and is known to block HIV-1 viral replication in human 
cell line experiments (Vlietinck et al., 1998). It is isolated 
from certain plants of Asteraceae and possesses antiviral 
and anticancer effects (Afendi et al., 2012). With a docking 
score of -7.65 kcal/mol, it formed three hydrogen bonds 
with active site residues LYS180, GLU252 and LYS218. 
Hydrophobic interactions with ARG179, HIS215, 
HIS215, GLU252, SER182, ARG179, PHE181, LYS180, 
SER182 and PHE181. The intermolecular energy was -
10.04 kcal/mol, and the total internal energy change was 
-1.97 kcal/mol. The docking results for the control 
compound and the above discussed best hits are 
summarized as presented in Table I followed by Figure 
1 visualizing the interactions of compounds with VP30. 
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Table I. Molecular docking results of control and the best 
two test compounds 
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2.71 
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2.76 
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Lys183 
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Leu218 
Gly220 
Gly219 
Leu188 
6-
Hydroxyluteolin 
-7.71 6 Lys180 
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Lys218 
Asp217 
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Figure 1. The ribbon structure of VP30 docked with (a) 
BCX4430, (b) 6-Hydroxyluteolin and (c) (-)-Arctigenin shown 
as ball and stick appearance (left) and their respective 
interacting residues (right). 
 
Bioactivity score prediction 
In general, bioactivity score of more than 0.0 indicates the 
complex is active whereas if the score is between -5.0 and 
0.0 the compound is moderately active and if the score is 
less than -5.0 it is probably inactive. The scores for the test 
compounds are listed in Table II, which indicates that 
both these test compounds possess bioactive properties 
of potential drugs as all the scores were above –5.0 and 
0.0 (Joshi et al., 2018).  
Table II. Molecular docking results of control and the best 
two test compounds 
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BCX4430 0.58 0.28 0.58 -0.74 0.09 1.39 
6-
Hydroxyluteolin 
-0.07 -0.17 0.26 0.25 -0.27 0.25 
(-)-Arctigenin 0.22 -0.02 0.00 0.13 0.10 0.20 
 
In the current scenario, EBOV–host interactions are still 
being explored where it is challenging to develop 
effective drugs and vaccines against EVD, and there is no 
detailed report of pharmacological inhibition against 
Ebola virus (Yu et al., 2017). The current strategy being 
symptomatic management emphasizes the need for 
targeted drug therapy. High throughput drug screening 
involving lead optimization, ADMET analysis, animal 
models and clinical trials is time-consuming, 
cumbersome and cost-ineffective (Sneha & Doss, 2016). 
Here is where computational studies substantially aid 
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experimental biology in designing potential drugs within 
a short period. 
Several in silico studies for Ebola virus have been reported 
targeting VP40 and VP35 to inhibit the activity of viral 
polymerase and viral assembly (Baikerikar, 2017). 
However, recent advances exploring the role of VP30 in 
transcription initiation enables it to be an attractive target 
though there is no much report with this regard. This 
study aims to explore the drug target potentiality of 
VP30. Compounds were screened using ADMET 
analysis and narrowed down for molecular docking. 6-
Hydroxyluteolin and (-)-Arctigenin were identified as 
promising lead molecules since they are permeable, non-
toxic, non-mutagenic and possess higher binding 
affinities than the control compound. Therefore, they can 
bind to the transcription initiation factor VP30 and block 
viral proliferation at a much earlier stage than the other 
targets. 
Out of the two investigated compounds, 6-
Hydroxyluteolin had the least binding energy of all and 
with six hydrogen bonds, which is higher in comparison 
to the control compound. Higher the number of 
hydrogen atoms greater is the stability (Saleh & 
Elshemey, 2017). Though the compound (-)-Arctigenin 
formed a lesser number of hydrogen bonds in 
comparison to BCX4430, it had lower binding energy 
pointing to the hydrophobic interactions making the 
compound more favourable for stable binding. The 
intermolecular energy for both the test compounds was 
considerably lower than that of the control. Moreover, the 
bioactive prediction scores again support the properties 
of their drug-likeness. Notably, plant-derived 
compounds, especially flavonoids, are potent inhibitors 
of Ebola viral disease, as suggested by earlier reports (Raj 
& Varadwaj, 2016). 
 
 
CONCLUSION 
With persistent periodical outbreaks, it is a high priority 
to developing a potential drug to resist Ebola viral 
disease. In an attempt to explore if VP30, transcription 
initiation protein of EBOV can function as a potential 
drug target for structure-based drug design. The study 
revealed that the two plants derived compounds 6-
Hydroxyluteolin and (-)-Arctigenin are potential lead 
molecules with the least binding energy and active 
biopredictivity scores. However, the solidity and 
efficiency should be validated using in vivo 
experimentations and clinical trials. These compounds 
identified as potential inhibitors of VP30 functional 
activity can be used for extensive drug design studies 
against EBOV study shortly. 
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